Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors

Inclusion Criteria

• •Male or female Chinese subjects \>/- 18 years
• •Advanced, histologically or cytologically confirmed solid tumors
• •Subjects malignancies must be refractory to standard treatment or have no standard therapy available, or the subject actively refused any treatment that would be regarded standard, and/or if, in the judgment of the investigator or his/her designated associate(s), experimental treatment is clinically and ethically acceptable.
• •Eastern Cooperative Oncology Group performance status (ECOG-PS) 0-1;
• •Adequate bone marrow, liver and renal function
• •Life expectancy of at least 3 months